Surgical Cytoreduction of the Primary Tumor Reduces Metastatic Progression in a Mouse Model of Prostate Cancer

Overview

Journal Oncol Rep

Specialty Oncology

Date 2015 Oct 28

PMID 26503286

Citations 13

Authors

Federico F Cifuentes

Rodrigo H Valenzuela

Hector R Contreras

Enrique A Castellon

Affiliations

Soon will be listed here.

Abstract

Metastatic prostate cancer (mPCa) is one of the most prevalent cancers in men worldwide. The main cause of death in these patients is androgen-resistant metastatic disease. Surgery of the primary tumor has been avoided in these patients as there is no strong evidence that supports a beneficial effect. From the biological point of view, it appears rational to hypothesize that the primary tumor may contribute to the establishment and growth of metastases. Considering this, we propose that cytoreductive surgery (CS) in advanced metastatic stage slows the progression of metastatic disease. To test this, we used a mouse model of resectable orthotopic prostate cancer (PCa) and performed CS. After surgery, metastases were smaller and less numerous in the treated mice; an effect that was observable until the end of the experiment. These results suggest that CS alone delays the progression of metastatic disease and that although this effect may be temporary, it may translate to prolonged survival, especially when used with adjuvant therapy.

Citing Articles

Comparison of Complications and Mid-term Results for Patients who Underwent Open Radical Prostatectomy for High-Risk and Oligometastatic Prostate Cancer: A Cross-Sectional Study from a Tertiary Reference Center.

Beyatli M, Duvarci M, Uzel T, Aybal H, Hamidi N, Ceylan O Ann Surg Oncol. 2024; 31(12):8438-8443.

PMID: 39196474 DOI: 10.1245/s10434-024-16104-z.

Minimally invasive cytoreductive radical prostatectomy, exploring the safety and feasibility of a single-port or multi-port robotic platform.

Lama D, Thomas K, Vernez S, Okunowo O, Lau C, Yuh B BMC Urol. 2024; 24(1):72.

PMID: 38532371 PMC: 10964602. DOI: 10.1186/s12894-024-01463-2.

The role of cytoreductive radical prostatectomy and lymph node dissection in bone-metastatic prostate cancer: A population-based study.

Zhai T, Ma J, Liu Y, Li H, Peng Y, Guo W Cancer Med. 2023; 12(16):16697-16706.

PMID: 37366247 PMC: 10501265. DOI: 10.1002/cam4.6292.

Immune determinants of the pre-metastatic niche.

Patras L, Shaashua L, Matei I, Lyden D Cancer Cell. 2023; 41(3):546-572.

PMID: 36917952 PMC: 10170403. DOI: 10.1016/j.ccell.2023.02.018.

Cancer Stemness/Epithelial-Mesenchymal Transition Axis Influences Metastasis and Castration Resistance in Prostate Cancer: Potential Therapeutic Target.

Castellon E, Indo S, Contreras H Int J Mol Sci. 2022; 23(23).

PMID: 36499245 PMC: 9736174. DOI: 10.3390/ijms232314917.

References

Shackleton M, Quintana E, Fearon E, Morrison S . Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 2009; 138(5):822-9. DOI: 10.1016/j.cell.2009.08.017. View

Ghajar C, Peinado H, Mori H, Matei I, Evason K, Brazier H . The perivascular niche regulates breast tumour dormancy. Nat Cell Biol. 2013; 15(7):807-17. PMC: 3826912. DOI: 10.1038/ncb2767. View

Husemann Y, Geigl J, Schubert F, Musiani P, Meyer M, Burghart E . Systemic spread is an early step in breast cancer. Cancer Cell. 2008; 13(1):58-68. DOI: 10.1016/j.ccr.2007.12.003. View

Antonyak M, Cerione R . Microvesicles as mediators of intercellular communication in cancer. Methods Mol Biol. 2014; 1165:147-73. DOI: 10.1007/978-1-4939-0856-1_11. View

Chapin B, McGuire S, Aparicio A . Is treatment of the primary tumor in metastatic prostate cancer justified?. Eur Urol. 2014; 65(6):1067-8. DOI: 10.1016/j.eururo.2013.12.011. View

Demicheli R, Retsky M, Hrushesky W, Baum M, Gukas I . The effects of surgery on tumor growth: a century of investigations. Ann Oncol. 2008; 19(11):1821-8. DOI: 10.1093/annonc/mdn386. View

Qin X, Ma C, Ye D, Yao X, Zhang S, Dai B . Tumor cytoreduction results in better response to androgen ablation--a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancer. Urol Oncol. 2010; 30(2):145-9. DOI: 10.1016/j.urolonc.2010.02.010. View

Valenca L, Sweeney C, Pomerantz M . Sequencing current therapies in the treatment of metastatic prostate cancer. Cancer Treat Rev. 2015; 41(4):332-40. DOI: 10.1016/j.ctrv.2015.02.010. View

Sceneay J, Smyth M, Moller A . The pre-metastatic niche: finding common ground. Cancer Metastasis Rev. 2013; 32(3-4):449-64. DOI: 10.1007/s10555-013-9420-1. View

10.

Krabbe L, Haddad A, Westerman M, Margulis V . Surgical management of metastatic renal cell carcinoma in the era of targeted therapies. World J Urol. 2014; 32(3):615-22. DOI: 10.1007/s00345-014-1286-5. View

11.

Clamage D, Sanford C, Vander A, Mouw D . Effects of psychosocial stimuli on plasma renin activity in rats. Am J Physiol. 1976; 231(4):1290-4. DOI: 10.1152/ajplegacy.1976.231.4.1290. View

12.

Kaplan R, Riba R, Zacharoulis S, Bramley A, Vincent L, Costa C . VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005; 438(7069):820-7. PMC: 2945882. DOI: 10.1038/nature04186. View

13.

Neeman E, Ben-Eliyahu S . Surgery and stress promote cancer metastasis: new outlooks on perioperative mediating mechanisms and immune involvement. Brain Behav Immun. 2012; 30 Suppl:S32-40. PMC: 3423506. DOI: 10.1016/j.bbi.2012.03.006. View

14.

Nguyen D . Tracing the origins of metastasis. J Pathol. 2010; 223(2):195-204. DOI: 10.1002/path.2801. View

15.

Tu S, Lin S . Prostate cancer stem cells. Clin Genitourin Cancer. 2012; 10(2):69-76. PMC: 4141775. DOI: 10.1016/j.clgc.2012.01.002. View

16.

Yu C, Shiozawa Y, Taichman R, McCauley L, Pienta K, Keller E . Prostate cancer and parasitism of the bone hematopoietic stem cell niche. Crit Rev Eukaryot Gene Expr. 2012; 22(2):131-48. PMC: 3615416. DOI: 10.1615/critreveukargeneexpr.v22.i2.50. View

17.

Faiena I, Singer E, Pumill C, Kim I . Cytoreductive prostatectomy: evidence in support of a new surgical paradigm (Review). Int J Oncol. 2014; 45(6):2193-8. PMC: 4215584. DOI: 10.3892/ijo.2014.2656. View

18.

Culp S, Schellhammer P, Williams M . Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 2013; 65(6):1058-66. DOI: 10.1016/j.eururo.2013.11.012. View

19.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

20.

Verhagen P, Schroder F, Collette L, Bangma C . Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review. Eur Urol. 2010; 58(2):261-9. DOI: 10.1016/j.eururo.2010.05.027. View